Synthetic Biology
Home / Services / By Technology / Protein Engineering Services / Protein Modification and Labeling Services / Protein PEGylation / Therapeutic Protein PEGylation Services
Trusted by Leading Research & Pharma Institutions

Therapeutic Protein PEGylation Services

Enhance therapeutic efficacy through advanced polyethylene glycol conjugation technology. Extend half-life, improve stability, and reduce immunogenicity of your protein therapeutics with our precision engineering solutions.

>89% Efficiency
30+ Approved Drugs
5-40 kDa Range
Learn More

Trusted by leading research and pharmaceutical institutions

Harvard
Pfizer
MIT
Roche
Stanford
Novartis

Why Choose Us

30+ FDA-approved PEGylated drugs
>89% conjugation efficiency
>95% product purity
Complete documentation

Extended Half-Life

From minutes to days circulation time

Reduced Immunogenicity

Minimized anti-drug antibodies

Enhanced Solubility

Improved formulation options

Market CAGR
12.5%
Overview Technology Specifications Workflow Applications FAQ
Service Overview

Professional PEGylation Services for Protein Therapeutics

Transform your protein therapeutics with our comprehensive PEGylation solutions. We deliver homogeneous, site-specific conjugates that maintain biological activity while significantly improving pharmacokinetic profiles.

Extended Half-Life

Increase circulation time from minutes to days, enabling less frequent dosing and improved patient compliance. The hydrodynamic volume increase from PEG conjugation reduces renal filtration.

  • Reduced dosing frequency from daily to weekly
  • Improved patient adherence
  • Sustained therapeutic drug levels

Reduced Immunogenicity

PEG's hydrophilic shell masks antigenic determinants, minimizing immune response against your therapeutic proteins. This is particularly important for chronic therapies.

  • Decreased anti-drug antibody formation
  • Reduced risk of infusion reactions
  • Improved long-term tolerability

Enhanced Solubility

Improve aqueous solubility of hydrophobic proteins, enabling better formulation options and reducing aggregation tendency.

Site-Specific Control

Precision conjugation at predetermined locations preserves bioactivity and ensures batch-to-batch consistency.

Regulatory Pathway

Well-defined product attributes and complete documentation facilitate regulatory acceptance.

Ready to Optimize Your Protein Therapeutic?

Get a customized quote for your PEGylation project.

Technology Platform

Advanced PEGylation Chemistry Platforms

Multiple PEGylation strategies to meet your specific protein engineering requirements.

N-Terminal Selective PEGylation

Reductive amination targeting the alpha-amino group at the protein N-terminus. Achieves >80% selectivity at optimized pH 5.5-7.0.

>80% Selectivity Mild Conditions

Cysteine-Directed PEGylation

Maleimide-mediated thiol-selective chemistry for site-specific modification. Engineered cysteine residues enable precise control over conjugation site.

>95% Selectivity Stable Linkage

Transglutaminase-Mediated PEGylation

Enzyme-catalyzed isopeptide bond formation at specific glutamine residues. The natural enzymatic process ensures mild conditions and high specificity.

>90% Selectivity Reproducible

Quality Control

MS ESI-MS and MALDI-TOF analysis
HPLC RP-HPLC for purity assessment
IEX Ion-exchange for charge variants
SEC SEC-HPLC for aggregate detection

PEG Reagent Portfolio

NHS mPEG-NHS esters (2-40 kDa)
MAL mPEG-maleimide derivatives
ALD mPEG-aldehyde (reductive amination)
Click Azide/alkyne functionalized PEG
Specifications

Technical Parameters

Flexible service options accommodating diverse project requirements from research through preclinical development.

Parameter Specification
Protein Size Range 5 kDa - 150 kDa
PEG Molecular Weight 2 kDa, 5 kDa, 10 kDa, 20 kDa, 30 kDa, 40 kDa
PEG Architecture Linear, Monodisperse, Branched (Y-shape)
Conjugation Efficiency >89%
Product Purity >95%
Scale Range 10 mg - 10 g
Reaction Time 2-24 hours
Quality Grade Research, Preclinical, GMP-like
Workflow

End-to-End PEGylation Workflow

From initial consultation to final product delivery, our streamlined process ensures quality and efficiency.

1

Consultation

Project requirements review

2

Feasibility

Condition optimization

3

Scale-Up

Production at target scale

4

Characterization

Complete analytical package

5

Delivery

Documentation and release

Applications

Therapeutic Applications

PEGylation enhances therapeutic performance across multiple drug modalities.

Therapeutic Proteins

PEGylated proteins have transformed treatment for chronic diseases including hepatitis, renal anemia, and growth disorders. Site-specific modification preserves activity while dramatically extending half-life.

  • Interferons for hepatitis treatment
  • Erythropoietin for anemia
  • Growth hormones for deficiency
  • Enzyme replacement therapies
30+
FDA-Approved PEGylated Drugs

Peptide Therapeutics

Peptides like GLP-1 analogs benefit enormously from PEGylation, which protects against enzymatic degradation and reduces rapid renal clearance. Weekly dosing regimens are now possible.

  • GLP-1 receptor agonists
  • Antimicrobial peptides
  • Hormone analogs
  • Cell-penetrating peptides
10-50x
Half-life Extension

Antibody Fragments

PEGylation of antibody fragments enhances their pharmacokinetic properties while maintaining target specificity and tissue penetration advantages of smaller formats.

  • Single-domain antibodies
  • Fab fragments
  • ScFv fragments
  • Bispecific formats
>90%
Activity Retention
Testimonials

What Our Partners Say

Trusted by researchers worldwide for quality and reliability.

The site-specific PEGylation service exceeded our expectations. Their team's expertise helped us achieve a homogeneous product with significantly improved pharmacokinetics.

R
Principal Scientist
Biotechnology Company

Working with their analytical team was seamless. The comprehensive characterization package provided everything we needed for our IND submission, including detailed PEG site mapping.

P
Research Director
Pharmaceutical Company

The DoE-based process optimization saved us months of development time. We achieved our target conversion rates and purity within the first campaign.

L
Lead Researcher
Academic Research Institution
Scientific Literature

Supporting Research

Our platform is backed by peer-reviewed research.

85 Citations

PEGylated therapeutics in the clinic

Gao Y, Joshi M, Zhao Z, Mitragotri S. Bioeng Transl Med. 2023.

Comprehensive review of over 30 FDA-approved PEGylated drugs across different therapeutic modalities.

View DOI
42 Citations

Research progress on the PEGylation of therapeutic proteins and peptides

Li C, Liu T, Tian X, et al. Frontiers in Pharmacology. 2024.

Latest advances in PEGylation technology including PEG properties, modification sites, and therapeutic applications.

View DOI
18 Citations

Engineering active lysostaphin variants with site-specific PEGylation

Batugal T, Pendyala G, Tomasovic L, et al. Biotechnology and Bioengineering. 2023.

Noncanonical amino acid incorporation and click chemistry for orthogonal site-specific PEGylation.

View DOI
76 Citations

Genetic Code Expansion Enables Site-Specific PEGylation of a Human Growth Hormone Receptor Antagonist through Click Chemistry

Tamshen K, Wang Y, Jamieson SMF, Perry JK, Maynard HD. Bioconjugate Chemistry. 2020.

Genetic code expansion for precise PEG attachment site control with >89% conjugation efficiency.

View DOI
52 Citations

From Synthesis to Characterization of Site-Selective PEGylated Proteins

Herrera L, Rangel-Yagui CO, Beltrán-Lissabet JF, et al. Frontiers in Pharmacology. 2019.

Review of chemical and enzymatic methods for site-selective PEGylation emphasizing homogeneous product advantages.

View DOI
FAQ

Frequently Asked Questions

What are the advantages of PEGylation for protein therapeutics?
PEGylation provides three key benefits: extended half-life through reduced renal clearance and proteolytic degradation, reduced immunogenicity by masking antigenic epitopes, and improved solubility/formulation for hydrophobic proteins. These advantages enable less frequent dosing and improved patient compliance.
How do you determine the optimal PEG size?
PEG size selection depends on your target indication, dosing route, and desired half-life. Smaller PEGs (1-5 kDa) are suitable for small proteins where minimal steric hindrance is critical. Larger PEGs (10-40 kDa) provide extended half-life for larger proteins but may impact activity. We optimize based on structure-activity relationships.
What PEGylation methods do you offer?
We offer multiple PEGylation strategies: N-terminal selective PEGylation using reductive amination, cysteine-directed PEGylation with maleimide chemistry, transglutaminase-mediated conjugation for glutamine residues, and click chemistry (CuAAC/SPAAC) for azide/alkyne functionalized proteins.
What characterization methods are included?
Every project includes comprehensive characterization: intact mass analysis by LC-MS, peptide mapping for site determination, SEC-HPLC for purity and aggregation, ion-exchange chromatography for charge variants, SDS-PAGE for molecular weight confirmation, and functional assays for bioactivity verification.
Can you support GMP manufacturing?
Yes, we offer GMP-compatible and full cGMP manufacturing services for clinical trial material. Our facilities support production from 10 mg to 10 g scales with complete regulatory documentation packages for IND/CTA submissions.
How long does a typical project take?
Standard projects are completed within 4-6 weeks including feasibility studies and characterization. Complex site-specific projects may take 6-10 weeks. GMP manufacturing campaigns typically require 3-6 months from initiation to product release.
What PEG reagents do you have available?
We maintain an extensive inventory including: mPEG-NHS esters (2-40 kDa), mPEG-maleimide derivatives, mPEG-aldehyde, mPEG-vinylsulfone, azide/alkyne functionalized PEG, branched PEG reagents (Y-shape, multi-arm), and heterobifunctional PEG linkers.
How do you handle proteins with multiple reactive sites?
For proteins with multiple reactive sites, we employ site-directed mutagenesis to introduce or remove specific residues, use enzymatic methods with inherent specificity, or engineer the protein to have only one accessible reactive site.
What is your typical conjugation efficiency?
Our site-specific methods typically achieve >89% conjugation efficiency with high site selectivity. Random PEGylation methods may result in mixtures, but our optimization ensures consistent product profiles. Final purity after purification is typically >95%.
Do you offer process development services?
Absolutely. Our DoE-driven process development identifies critical process parameters and optimizes conjugation conditions for yield, selectivity, and scalability. We provide comprehensive process characterization reports and tech transfer packages.

Ready to Start Your Project?

Get a customized quote for your Therapeutic Protein PEGylation Services project. Our experts will respond within 24 hours.

No obligation
24h response
Expert consultation

Recommended Services

· PEGylation Services for Antibody Fragments (Fab, scFv)
· PEGylation Services for Cytokines and Enzymes

Related Resources

· Cost and Efficiency Analysis of CRlSPR-Cas9 Knockout Services in Mice and Cell Lines
· Validating CRISPR Knockouts: Best Practices for qPCR, Sequencing, and Functional Assays
· Step-by-Step Guide to Generating CRISPR Knockout Cell Lines for Research
Quick Links

Home

Products

Services

About Us

Contact Us

Follow Us
CONTACT US

USA

Tel:

Email:

Japan

Tel:

Email:

Korea

Tel:

Email:

Copyright © 2026 CD Biosynsis. All rights reserved.